Tesamorelin half-life in blood
The molecule leaves blood quickly. The hormonal response has its own duration, which complicates a simple answer about time in the system.
Human estimates and animal measurements
The commonly cited human range is 26–38 minutes, a secondary estimate from prescribing-label summaries. Half-life describes the time for the amount in blood to fall by half; it gives no exact moment at which every trace or effect has disappeared.
The early experimental paper with explicit elimination measurements reported 21–45 minutes in dogs after intravenous or subcutaneous administration. Its tests reached 600 microg/kg in dogs. That is an animal study amount, with no human dosing implication. The paper also tested degradation in plasma outside the body.
I’m wary of a single crisp minute count travelling without its species attached. The animal measurements and the secondary human estimate both describe short exposure, but they have different origins. The published human exposure-response analysis addresses how tesamorelin exposure relates to growth hormone and IGF-1; it supplies a different kind of information.
How long does tesamorelin stay in your system?
The answer depends on whether “tesamorelin” means the parent molecule in blood or the response it started. The drug is rapidly cleared, while IGF-1 remains elevated across the daily interval studied. The healthy-men hormone study and human exposure-response model describe that longer hormonal response.
I understand the timing as two durations: short plasma exposure and a longer response in the GH/IGF-1 system. Neither a half-life range nor a clearance estimate can establish when all biological effects end.
The pulmonary experiment in beagles
The 2004 pulmonary-delivery study explored dry powder delivered into beagles’ airways. Relative bioavailability was 41% compared with subcutaneous injection; absolute bioavailability was 13%. The first percentage compares routes, while the second concerns the fraction of the administered amount reaching circulation.
Terminal half-life was 39 minutes after pulmonary delivery and 26 minutes after subcutaneous injection. Mean residence time was 74 versus 52 minutes. Mean residence time summarizes the average time drug molecules remain in the body; it answers a different question from half-life.
I hadn’t expected lungs to feature in this history. The experiment shows an attempted route of delivery and its limits. It remained dog research, and it never became an approved inhaled tesamorelin medicine for people.
Timing and the trial regimen
The pivotal abdominal-fat trial used daily subcutaneous treatment. A short-lived signal can produce a longer-lived hormonal response, which helps explain the interval researchers studied.
I can’t extract an injection schedule or a sports-test detection window from a half-life estimate. The dose page records the historical study amounts, and the mechanism page describes the hormone response that makes the timing interesting.